ReproCELL Inc. | Balance Sheet

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
Cash & Short Term Investments
5,171
4,918
5,409
5,420
5,580
Total Accounts Receivable
67
117
141
126
132
Inventories
69
235
272
322
243
Other Current Assets
36
90
40
42
24
Total Current Assets
5,343
5,360
5,861
5,911
5,980
Net Property, Plant & Equipment
16
48
62
96
72
Total Investments and Advances
50
63
106
347
535
Intangible Assets
3
2,108
1,905
1,469
1
Other Assets
6
15
34
32
9
Total Assets
5,419
7,594
7,968
7,854
6,598
ST Debt & Current Portion LT Debt
-
-
5
3
2
Accounts Payable
49
61
105
84
71
Income Tax Payable
12
17
18
31
34
Other Current Liabilities
75
221
327
164
154
Total Current Liabilities
136
299
456
282
261
Long-Term Debt
80
80
86
83
80
Provision for Risks & Charges
7
7
7
7
7
Deferred Taxes
1
123
151
114
1
Other Liabilities
-
-
1
-
-
Total Liabilities
223
509
700
486
349
Common Equity (Total)
5,195
7,085
7,268
7,369
6,248
Total Shareholders' Equity
5,195
7,085
7,268
7,369
6,248
Total Equity
5,195
7,085
7,268
7,369
6,248
Liabilities & Shareholders' Equity
5,419
7,594
7,968
7,854
6,598

About ReproCELL

View Profile
Address
KDX Shin-Yokohama 381 Building, 9/F
Yokohama Kanagawa 222
Japan
Employees -
Website http://www.reprocell.com
Updated 09/14/2018
ReproCELL Inc. engages in the development of diverse products with an underlying theme that focuses on stem cell technology. It operates through the following business divisions: Induced Pluripotent Stem (iPS)/Embryonic Stem (ES) Cells and Clinical Testing. The Induced Pluripotent Stem (iPS)/Embryonic Stem (ES) Cells division handles the manufacture and sale of research reagents, and the production and evaluation of cells.